New stock news | Yino Micro Medicine submits its application to the Hong Kong Stock Exchange for the third time.

According to the financial news app Zhitong Finance, as disclosed by the Hong Kong Stock Exchange on July 16th, Immvira Bioscience Inc. (referred to as Yino Micro Medicine) has submitted an application for listing on the main board of the Hong Kong Stock Exchange, with Citigroup and China International Capital Corporation serving as joint sponsors. According to the prospectus, Yino Micro Medicine is a clinical demand-oriented biotechnology company dedicated to discovering, developing, producing, and commercializing novel oncolytic immunotherapy and engineered exosome therapy. The company has established a product pipeline, including two oncolytic immunotherapy products for solid tumors and five engineered exosome products with clinical applications or potential for direct commercialization.